Jul 2026
An allogeneic CD19 targeted Engineered Treg approach for treating B cell mediated autoimmune diseases 2260315
GNTI-350 can safely achieve a durable immune reset and may provide superior therapeutic benefit over CAR-T approaches to patients with B cell—driven autoimmune diseases.
P. Zarin, Chris B. Moore, Travis Drow et al.
· Journal of Immunology · 0 citations